Cut to the chase: On the need for genotype-specific soft tissue sarcoma trials

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 399-400

  Gupta, A ^a   Church, D ^a   Barnes, D ^a   Hassan, A B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; IFOSFAMIDE; RAPAMYCIN;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; EDITORIAL; EWING SARCOMA; GENE MUTATION; GENOTYPE; HUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

EID: 61649124903     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp021     Document Type: Editorial

References (13)

1. Italiano A, Penel N, Robin YM et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: A study of the French Sarcoma Group. Ann Oncol 2008; 20: 425-430.
2. Juergens C, Weston C, Lewis I et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47: 22-29.
3. Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol 2006; 7: 444-455.
4. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350: 1647-1654.
5. Le Cesne A, Van Glabbeke M, Woll PJ et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials. J Clin Oncol 2008; 26 (Suppl 155): 10525.
6. van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002; 38: 2397-2406.
7. Davis SR, Meltzer PS. Modeling synovial sarcoma: Timing is everything. Cancer Cell 2007; 11: 305-307.
8. dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 2001; 30: 1-14.
9. Sun Y, Gao D, Liu Y et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006; 25: 1042-1052.
10. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: An analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005; 16: 437-444.
11. Canter RJ, Qin LX, Maki RG et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 2008; 14: 8191-8197.
12. Ito T, Ouchida M, Morimoto Y et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005; 224: 311-319.
13. Lubieniecka JM, de Bruijn DR, Su L et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008; 68: 4303-4310.